VJHemOnc is committed to improving our service to you

ICML 2019 | Bispecific AFM13 plus pembro for R/R Hodgkin lymphoma

VJHemOnc is committed to improving our service to you

Stephen Ansell

AFM13 is a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. Here Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the trial of AFM13 plus pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure (NCT02665650). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter